QureBio
Shanghai
About QureBio
QureBio focuses on the research and development of innovative macromolecular biopharmaceuticals. Its goal is to develop new therapeutic drugs for the treatment of refractory cancer, autoimmune diseases, and metabolic diseases in China and the world to benefit patients. QureBio has multiple technology platforms for antibody drug development including phage display technology platforms and hybridoma antibodies technology platform and monoclonal antibody platform. The company was founded in 2017 and is based in Pudong District, Shanghai.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Total funding: $46.6M
- Funding stage: Late Stage Venture
- Last round: Series C (Jun 2025)
- Website: qurebio.com
- Phone: +86 136 2177 2640
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/qurebio-91706 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.